Stay in touch
Prime news from our network.
#read
BioNTech acquires Biotheus to strengthen its oncology strategy
BioNTech plans to acquire the biotechnology company Biotheus to expand its capabilities in the development, manufacturing and commercialisation of bispecific antibodies and innovative combination therapies. With the acquisition, BioNTech secures the worldwide rights to BNT327/PM8002, a bispecific antibody that could represent an alternative to existing checkpoint inhibitors in solid tumours.
13/11/2024
The transaction includes an upfront payment of USD 800 million and up to USD 150 million in milestone payments. The transaction is expected to close in the first quarter of 2025. Several clinical trials with BNT327/PM8002 are planned in 2024 and 2025, including in lung cancer and triple-negative breast cancer.
The acquisition also gives BioNTech access to Biotheus' expertise as well as a state-of-the-art manufacturing facility and research centre in China, strengthening BioNTech's global presence. Prof. Dr Ugur Sahin, CEO of BioNTech, emphasises the potential of BNT327/PM8002 as a new standard of care in oncology.The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.